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MANAGING VARIANT DISCREPANCY IN HEREDITARY CANCER: 
CLINICAL PRACTICE, BARRIERS, AND DESIRED RESOURCES 
Ellen Hope Zirkelbach, BS 
 
              Advisory Professor: Syed S. Hashmi, MD, MPH, Ph.D. 
Variants are changes in the DNA whose phenotypic effects may or may not be 
definitively understood. Because variant interpretation is a complex process, 
sources sometimes disagree on the classification of a variant, which is called a 
variant discrepancy. This study aimed to determine the practice of genetic 
counselors regarding variant discrepancies and to identify the barriers to 
counseling a variant discrepancy in hereditary cancer genetic testing. This 
investigation was unique because it was the first to address variant 
discrepancies from a clinical point of view. An electronic survey was sent to 
genetic counselors in the NSGC Cancer Special Interest Group. The vast 
majority of counselors (93%) had seen a variant discrepancy in practice. The 
most commonly selected barriers to counseling a variant discrepancy were lack 
of data sharing (90%) and lack of a central database (76%). Most counselors 
responded that the ideal database would be owned by a non-profit (59%) and 
obtain information directly from laboratories (91%). When asked how they 
approached counseling sessions involving variant discrepancies, the free 
responses emphasized that counselors consider family history and 
psychosocial concerns, showing that genetic counselors tailored the session to 
each individual. Variant discrepancies are an ongoing concern for clinical 
cancer genetic counselors, as demonstrated by the fact that counselors desired 
further resources to aid in addressing variant discrepancies, including a 
centralized database (89%), guidelines from a major organization (88%), 
continuing education about the issue (74%) and functional studies (58%). 
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INTRODUCTION 
        Evolving technologies have made it possible to examine the genome more 
thoroughly than ever before. With these technologies, such as next generation 
sequencing (NGS), challenges have arisen, including an increased need for variant 
annotation and interpretation. Variants are changes in the DNA whose phenotypic 
effects may or may not be definitively understood. For example, a variant may be found 
that is known to cause an increased lifetime risk of cancer. Alternatively, a variant may 
not be well understood, making it difficult to predict if it affects the lifetime risk of cancer 
for the patient.  
        The previously mentioned NGS technology led to the development of a style of 
genetic analysis called panel testing, which first became available in 2012 in cancer 
genetics (Kurian et al., 2014). Many providers are turning to panel testing using NGS 
since it is a cost-effective way to test many genes at once (Gallego et al., 2015). It has 
been shown that the number of variants detected increases with the number of genes 
sequenced (Lincoln et al., 2015). Therefore, the use of panel testing increases the 
chance of discovering variants in genes associated with greater risk of cancer. In fact, 
when 29 genes were sequenced in 1062 people, 41% had at least one variant and 
11.4% had two or more variants (Lincoln et al., 2015). When 20,000 genes were 
analyzed using whole exome sequencing (WES), variants of uncertain clinical 
significance (VUS) were found in 95% of the study population (Maxwell et al., 2016). The 
increasing rate of variant discovery has brought to light the importance of understanding 
the effects of these gene changes.   
        When a variant is identified, its pathogenicity must be determined. In the 2015 
Standards and Guidelines for the Interpretation of Sequence Variants, the American 
College of Medical Genetics and Genomics (ACMG) recommended a 5-tiered system for 
indicating pathogenicity: pathogenic (P), likely pathogenic (LP), variant of uncertain 
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significance (VUS), likely benign (LB), and benign (B) (Richards et al., 2015). According 
to these guidelines, laboratory classification of a variant should be based on multiple 
lines of evidence, including population data, disease databases, segregation data, 
scientific and medical literature, and in silico predictors (Richards et al., 2015). Some 
experts attest that the most useful sources of information include allele frequency, 
conservation data, co-segregation, and the mutation type (Amendola et al., 2015). 
Population data can be found in databases such as the Exome Aggregation Consortium 
(ExAC), 1000 Genomes, and the Exome Variant Server (EVS) (Richards et al., 2015). 
From these databases, the prevalence of the allele in the population can be ascertained. 
In general, the more rare the allele, the more likely it is to be pathogenic. Conservation 
data can be found through Genomic Evolutionary Rate Profiling (GERP) and Combined 
Annotation Dependent Depletion (CADD). The scores obtained through these services 
indicate similarity between species. A lower CADD or GERP score means less 
conservation between species, which is considered less likely to be pathogenic. Co-
segregation, another tool for analyzing variants, can determine if a variant tracks with the 
phenotype within a family. If the variant is present in family members with a disorder, it 
cannot be ruled out as benign. Lastly, certain mutation types are associated with an 
increased risk for pathogenicity. These include truncation of the gene, which implies an 
abbreviated protein product, and a de novo condition occurring with a de novo variant, 
which means both the condition and the gene change are new to the proband 
(Amendola et al., 2015). Based on the information obtained from many sources, the 
pathogenicity of a variant can be estimated, with varying degrees of certainty. 
        Once pathogenicity has been gauged, clinicians, including oncologists and genetic 
counselors, must determine the clinical utility of the results. The ACMG states that 
variants classified as either pathogenic or likely pathogenic are clinically actionable as 
the terms imply a greater than 90% certainty that the variant in question is truly disease-
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causing (Richards et al., 2015). In such circumstances, management decisions can be 
made based on pathogenicity, including prophylactic surgery and increased surveillance 
for tumors. This idea is oversimplified, however, because the classification of variants is 
not always straightforward. It has been shown that sources are not always concordant in 
variant interpretation. For example, one laboratory may call a variant a VUS, while 
another classifies it as likely pathogenic. Differences between laboratories may be due 
to varying testing techniques, such as use of unlike cell lines or different assays 
(Karbassi et al., 2016). The differences may also be due to discrepancies in variant 
analysis, such as weighing evidence differently and setting varying thresholds for 
pathogenicity. Another source of discrepancies may be that some researchers have 
access to information that others do not. For example, one laboratory may have an 
internal database of test results that are not shared with other laboratories (Amendola et 
al., 2015).   
        Many previous studies have analyzed the frequency of variant discrepancies. When 
nine Clinical Sequencing Exploratory Research (CSER) laboratories analyzed 97 
variants, the classification was concordant between all laboratories in only 19% of cases 
(Amendola et al., 2016). This number, however, may not be applicable to the clinical 
genetic counselor since it is very unlikely that a patient would be tested at nine different 
laboratories. Other more recent studies comparing annotations found in the ClinVar 
database to those from commercial genetic testing laboratories have found an 11.7% to 
26.7% rate of discordant variant classifications (Gradishar et al., 2017, Harrison et al., 
2017). 
In order to analyze the prevalence of discordant classification in cancer genes 
specifically, one study looked at agreement between databases for variants found in 
their subjects via WES. Classifications were discordant in 16% of cases involving an 
autosomal dominant cancer gene and 23% of cases involving an autosomal recessive 
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cancer gene. There was a 4% rate of disagreement in clinical actionability for autosomal 
dominant conditions, and a 9% rate for autosomal recessive. The same study found a 
17% discrepancy rate for all cancer and non-cancer genes, and an overall rate of 4% for 
disagreement on clinical actionability (Maxwell et al., 2015). Another study found that 
26% of cancer variants found via recruitment into the Prospective Registry of Multiplex 
Testing (PROMPT) had conflicting interpretations when compared to the ClinVar 
database. In addition, 11% of variants had classifications that differed in clinical 
actionability (Balmaña et al., 2016). Having up to 26% discordance in variant calling 
implies an issue for clinicians in a cancer setting, who may receive different 
classifications depending on the source reporting the result. This is especially troubling 
in up to 11% of cases when the classification provided by one source implies clinical 
actionability, while the classification from another source does not.         
        Because variant classifications can differ between sources, clinicians may have 
difficulty applying discrepant variant results in a clinical setting. This study aims to 
identify the strategies that clinical genetic counselors use to understand variant results, 
to determine current counseling practice when there is a discordant result, and to 
understand the barriers to counseling when there is a variant discrepancy in hereditary 
cancer testing. The results may inform future guidelines for clinical application of 
inconsistent variant annotation.  
METHODS 
Study Population 
        This study surveyed practicing cancer genetic counselors, specifically members of 
the National Society of Genetic Counselors (NSGC) Cancer Special Interest Group 
(SIG). An email was sent to Cancer SIG members explaining the basis of the study and 
inviting them to complete the survey. Participation in the survey constituted consent to 
the study, and counselors could opt to discontinue at any point in the survey. The 
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inclusion criteria consisted of, 1; being a board certified or board eligible genetic 
counselor working primarily in oncology, 2; spending more than 50% of their time in a 
clinical setting, and 3; having attended an accredited genetic counseling master’s 
program. These criteria excluded participants who had different experience and 
expertise than required for this study. Student members of the SIG were also excluded. 
Survey 
        The survey was created by the authors using Qualtrics software (2015) available 
through the University of Texas Health Science Center at Houston. It was distributed via 
email to members of the NSGC Cancer SIG in June 2016. Two reminder emails were 
sent in July and August 2016. The survey was closed on August 31, 2016. The survey 
took approximately 15-20 minutes for each participant to complete, and all answers were 
anonymous.  
        The survey was a semi-structured questionnaire with 32 questions. There were 7 
demographic questions that collected information about schooling and work setting. The 
next section evaluated the counselor’s strategies for assessing variant results. In this 
section, participants were asked questions about researching variants, including the 
lines of evidence they used and how often they researched variants independently. 
Counselors were then asked about their current counseling practice regarding variant 
discrepancies, including how often they identified a variant discrepancy and how they 
managed them in a clinical setting. There were two scenarios involving discovery of 
variant discrepancies, followed by questions about how participants would handle these 
situations. Lastly, there were questions regarding barriers to counseling when there are 
discordant variant results. At the end of the survey, the counselors had the option to 
input their email address to enter a drawing for a gift card. All research protocols met the 
requirements of the University of Texas Health Committee for the Protection of Human 
Subjects, and this study was assigned approval number HSC-MS-16-0436.  
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Statistics 
        STATA 14 software was used to analyze statistics (StataCorp, 2015). Primary 
outcomes included descriptive analyses. Results were reported as frequencies with 
percentages. Secondary explorative analysis was performed, using Fisher exact tests or 
t-tests based on the nature of the data, to compare differences between groups.  All 
comparative tests were considered significant at type I error rate of 5%. Free text 
responses were analyzed for similarities.  
RESULTS 
Demographics 
        There were 281 responses to the survey, which represented 33% of the largest 
mailing to 849 counselors. Twenty-five respondents did not complete the demographic 
information and therefore were excluded from the analysis. There were 24 respondents 
who met exclusion criteria, including current students and genetic counselors that did not 
work primarily in a clinical oncology setting. This left a total of 224 responses that were 
included in analysis. Of these, 60 (27%) were partially complete, and the answered 
questions were included in analysis. The demographic information of the respondents is 
reported in table 1.  
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Table 1: Demographics 
 Number of Respondents Percentage of Respondents 
Year graduated from a genetic counseling master’s program 
1971-1979 2 1 
1980-1989 15 7 
1990-1999 23 10 
2000-2009 49 22 
2010-2016 135 60 
Experience in cancer genetics in number of years 
0 to 5  145 65 
5+ to 10  39 18 
10+ to 15 21 9 
15+ to 20 12 5 
20+ 7 3 
Specialties counseled regularly 
Pediatric 34 15 
Breast  214 96 
Gynecological 211 95 
Endocrine 105 47 
Gastrointestinal 214 96 
Other* 12 5 
Licensure available in participant’s state 
Yes 102 45 
No 120 54 
Unsure 1 1 
*Other responses: Nine counselors indicated that they counsel all specialties 
(4%). One counselor indicated each of the following: “prostate” (1%), “leukemia” (1%), 
and “head, neck, renal, CNS” (1%).  
 
 
Strategies for Assessing Variant Results 
        The genetic counselors were asked a series of questions about how they approach 
a non-discrepant variant result provided by a laboratory. A large majority, 178 (96%) of 
counselors indicated that they conduct their own research on genetic testing results that 
report a variant. The most common line of evidence used in research was disease 
databases, with 148 counselors (83%) indicating that they use them “always” or “most of 
the time”. Other commonly used lines of evidence were mutation type, with 94 (53%) 
“always” or “most of the time” responses, and conducting a primary literature search, 
with 87 (49%) “always” or “most of the time” responses. One line of evidence that was 
less commonly used was functional studies, with 64 (36%) responses. Participants also 
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ranked the lines of evidence that were most informative when researching variants. 
Counselors were most likely to use the lines of evidence that they found the most 
informative (p=0.01 for mutation type, p<0.0001 for all other lines of evidence).  
        To further explore the attitudes of counselors about variant results, they were asked 
if their confidence in the classification of a single variant depended on the laboratory 
providing it. Of 213 respondents, 178 (83%) of counselors affirmed that their confidence 
does depend on the performing laboratory. To clarify, one respondent stated, “Not all 
labs - or classification systems - are created equally. Whichever lab was ‘better’…is the 
classification I would use for medical management”. 
Current Variant Discrepancy Counseling Practice 
        Of 180 participants, 167 (93%) had seen a variant discrepancy in practice and 111 
(62%) had come across a discrepancy on 3 or more occasions in the last 3 years. A total 
of 143 (78%) counselors found a discrepancy by searching the variant in a disease 
database. Eighty-five (46%), counselors indicated they discovered a discrepancy by 
using different laboratories to test relatives, 73 (40%) indicated testing two unrelated 
patients at different laboratories, and 29 (16%) indicated testing one patient at two 
different laboratories.  
        Those that indicated they refer to databases “always” or “most of the time” when 
researching variants were more likely to discover a discrepancy in a database 
(p<0.0001). However, this same group was not statistically more or less likely to discover 
discrepancies overall than those who refer to disease databases less often (p=0.518). 
There was also no statistical difference in the likelihood of identifying a variant 
discrepancy based on the type of testing most frequently ordered (p=0.254). Of our 213 
respondents, 186 indicated that they order panel testing most often (87%), 4 indicated 
that they order syndrome-specific testing most often (2%), and 23 indicated that they 
order the two about equally (11%). 
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        Of 181 counselors, 98 (54%) reported taking 1-15 minutes to research a non-
discrepant variant result. When asked how long it takes to research a discrepant variant 
with discordant classifications, 40 (24%) counselors indicated that it takes 46-60 
minutes, 39 (23%) counselors selected 16-30 minutes, and 31 (19%) selected 31-45 
minutes. There was a significant difference in the time spent researching a non-
discrepant variant versus a discrepant variant (p=0.001), with the majority of counselors 
spending more time researching a variant discrepancy than a non-discrepant variant 
(Figure 1). Of 160 respondents, 125 (78%) spent more time following up on a 
discrepancy than researching a single variant, and 4 (3%) spent less time. A total of 52 
(33%) counselors spent 45 minutes or more of extra time researching a discrepancy 
compared to researching a single variant. The amount of time a counselor spent 
following up on a discrepancy was not dependent on the number of discrepancies they 
had previously discovered (p= 0.482).  
Figure 1 
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        Scenarios were utilized to assess how respondents approach counseling sessions 
involving variant discrepancies. In scenario A, a variant in Hereditary Breast and Ovarian 
Cancer (HBOC) was classified by one laboratory as a VUS and by another as LP. Most 
counselors indicated that they would explain both classifications, explain how each 
classification was reached, emphasize that they are not the same, and discuss clinical 
management for each. In scenario B, a variant in a gene associated with Lynch 
Syndrome was classified by one laboratory as a VUS and by another other as LP. The 
same four responses were selected most often for this question (figure 2). For the 
majority of responses, those that selected a specific approach for the discrepancy in 
scenario A involving HBOC were statistically more likely to choose that same approach 
for the discrepancy in scenario B involving Lynch Syndrome. This is true for the following 
responses: explain both (p=0.015), explain how each classification was reached 
(p<0.0001), explain only VUS (p<0.0001), emphasize they are not the same (p<0.0001), 
and discuss clinical management for each (p<0.0001).  
Figure 2 
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        In scenario B, participants were also asked to select approaches to a counseling 
session involving a variant in a gene associated with Lynch syndrome that is classified 
as LP by one laboratory and P by another laboratory. Counselors were likely to respond 
similarly to this question as to the previous question in scenario B, mentioned above, 
where the variant is classified as LP and VUS (figure 3). This was the case for the 
following responses: explain both (p=0.014), explain how each classification was 
reached (p<0.0001), emphasize they are not the same (p=0.002), and discuss clinical 
management for each (p=0.032). In general, more counselors chose to emphasize that 
the classifications were not the same, with 121 (73%) respondents, and to discuss 
clinical management for each, with 148 (90%) respondents, when comparing LP and 
VUS. This is compared to 43 (26%) that chose to emphasize that the two classifications 
were not the same and 60 (36%) that chose to discuss clinical management when 
comparing LP and P (figure 3).  
 
Figure 3 
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        Both scenarios allowed counselors to write “other” responses to the questions. 
Many of these responses emphasized the importance of family history in deciding how to 
approach a counseling session involving a discrepancy and how to manage the patient’s 
care. For example, a respondent clarified that they “discuss the result in the context of 
family history and whether prophylactic surgery could be recommended based on family 
history alone.” The free responses also pointed out a focus on psychosocial support for 
the patient. One counselor explained that they “discuss psychosocial aspects of having 
discrepant test results and how that has impacted the patient.” 
Barriers to Counseling 
        When asked to select barriers to the genetic counseling process regarding variant 
discrepancies, 162 of 164 (99%) counselors selected at least one barrier. The most 
frequently selected barrier with 147 responses was lack of data sharing (90%), followed 
by 118 for lack of a central database (72%), 94 for lack of educational resources (60%), 
and 88 for legal liability for clinicians and laboratories (54%).  
        Participants were asked to indicate who should ideally input information into a 
centralized database, and 150 (95%) selected laboratories only or a combination of 
laboratories and another source. No participants chose patients as the sole source of 
information for a centralized database. A total of 96 respondents (59%) indicated that a 
non-profit should own such a database. Forty-four counselors (27%) chose government 
as the ideal owner of a centralized database.  
        Of 164 respondents, 115 indicated that they are concerned about legal liability 
when it comes to variant discrepancies (70%). Licensed genetic counselors were 
statistically more likely to indicate that they were concerned about legal liability than 
those that are not licensed (p=0.004). However, there is no statistical difference in the 
time that licensed and unlicensed counselors spend following up on variant 
discrepancies (p=0.203). In addition, there was no difference in follow-up time between 
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counselors who are concerned about legal liability and those that are not concerned 
about legal liability (p=0.205).  
        Lastly, counselors chose resources that would help in counseling when they come 
across a discrepancy (figure 4). The most common response selected by 148 (89%) 
counselors was additional support from the laboratories involved with the discrepancy, 
followed by 145 (88%) that chose practice guidelines from a major society/organization, 
121 (74%) that chose continuing education opportunities, and 95 (58%) that chose 
functional studies.  
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Frequency and Time Considerations 
        Clinical cancer genetic counselors should expect to come across the issue of 
variant discrepancies in practice, given that 93% of respondents saw at least one 
discrepancy in clinic. There was no difference in the number of discrepancies discovered 
by those who order panel testing, syndrome-specific testing, or both about equally. This 
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shows that cancer genetic counselors do not avoid encountering variant discrepancies 
by ordering syndrome-specific panels.  
        Most respondents to this survey discovered an average of one discrepancy per 
year, which is less prevalent than the 16-26% frequency of discrepancies in genes 
associated with cancer cited in the literature (Balmaña et al., 2016, Maxwell et al., 2015). 
Some previous studies, however, were looking at results that included many more genes 
that the typical cancer panel, which today contains anywhere from 2 to 80 genes. 
Studies show the more genes tested, the more likely there will be a variant found 
(Lincoln et al., 2015, Maxwell et al., 2016). Therefore, it is not surprising that the 
previous studies using WES found more discrepancies. It is important to note that the 
research in cancer genetics is constantly being updated, so it is likely that more genes 
will be gradually added to cancer panels and could increase the rate at which counselors 
see discrepancies in the future. Another reason that this study may have found a lower 
rate of discrepancies is that counselors ordering hereditary cancer testing may not 
research every result they get. Though 96% of our study population indicated 
researching variant results independently, it is possible certain classifications are more 
likely to trigger further research, particularly if there is suspicion that the result may not 
be appropriate for a patient’s clinical presentation or family history. If so, some 
discrepancies may not be discovered. 
        Researching a discrepant variant was more time-consuming than researching a 
non-discrepant variant. In fact, a third of counselors (33%) said they spend over 45 
minutes researching a variant discrepancy. This is concerning because it consumes the 
genetic counselor’s valuable clinic time. The time that counselors spent on a variant 
discrepancy was not dependent on the number of discrepancies seen, licensure status, 
or concern about legal liability. The fact that time spent was not dependent on how many 
times they had seen discrepancies demonstrates that prior experience did not impact the 
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amount of research time needed. None of these influenced the amount of time spent 
researching a discrepancy, so there must be some other factor that drove the 
differences between respondents that was not addressed in this survey.  
 Databases and Barriers to Counseling 
        The vast majority of respondents (96%) conducted their own independent 
assessment on variants using available resources, including the 87% of counselors who 
used disease databases. Disease databases were a widely utilized resource for 
counselors when researching variants, and our respondents reported this is the most 
frequently used line of evidence. This could be because many databases with 
information about variants are readily accessible online, such as the disease databases 
OMIM and ClinVar (Richards et al., 2015). Survey participants also reported that disease 
databases were the most common way to discover a variant discrepancy. However, 
those that refer to disease databases more often were not more likely to discover 
discrepancies than counselors who used them less often. This shows that counselors 
that did not use databases were not avoiding discovery of discrepancies. Other methods 
of discovery, in order from most commonly selected to least, were using different 
laboratories to test relatives, discovering the same variant in two patients tested at 
different laboratories, and testing one patient at two laboratories.  
        Our study demonstrates that very few counselors are satisfied with resources 
currently available to evaluate variant discrepancies given that a majority (99%) of 
respondents selected at least one barrier. The most commonly selected barrier was lack 
of data sharing followed by lack of a central database. Many obstacles would need to be 
addressed in order to overcome lack of data sharing and create a central database. One 
of these obstacles is curation. This includes the responsibility of updating the information 
and ensuring common standardized nomenclature. Furthermore, some may feel that 
sharing data means that others can make monetary gain from their work (Savage, 
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2017). In addition, current databases have limited amount of phenotypic information 
available about the patient with the variant, making it difficult to know if the variant is 
clinically significant (Johnston et al., 2013).  
        Despite these obstacles, there are efforts underway to help reconcile the deficit of a 
central database. One example is the Prospective Registry of Multiplex Testing 
(PROMPT), which allows patients to self-enroll by inputting their panel testing results. 
This registry allows data sharing through patient input and allows comparison of variant 
classifications (Balmaña et al., 2016). Another database, BRCAShare, gathers 
information about variants in the BRCA1 and BRCA2 genes. The data is obtained from 
the Universal Mutation Database owned by the French Unicancer Genetic Group, along 
with data from two commercial testing laboratories. This effort combines academic and 
commercial knowledge into a central database (Rehm et al., 2015). However, 
BRCAShare only gathers information for two of the many known cancer genes, so much 
more is needed in the ideal database. There are other available resources, including 
ClinVar, which is an initiative from the National Institute of Health that gathers 
information about variants associated with many diseases including cancer, and GENIE, 
which is an effort from the American Association for Cancer Research that gathers 
patient information and genomic results (Savage, 2017).  
        This study clarified the ideal source for inputting data into databases and the ideal 
owner of a centralized database. The majority of counselors (95%) indicated that the 
laboratory alone or the laboratory combined with another source should input variant 
data into a centralized database. Most survey participants (59%) indicated that a non-
profit should own such a database and about a quarter (27%) of respondents selected 
government as the ideal owner. Based on these responses, counselors desire that 
laboratories input information into a central database that is owned by a non-profit 
organization without a potential conflict of interest.  
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Approaching the Counseling Session 
        When it comes to patient care involving variant discrepancies, counselors were 
consistent in their approach regardless of the hereditary cancer syndrome involved. 
Additionally, counselors were statistically likely to choose the same approaches to the 
session whether or not there was a difference in clinical actionability of the 
classifications. When there was a discrepancy in actionability, counselors were more 
likely by percentage to emphasize that the classifications were not the same and to 
discuss management based on each classification.  
        The free response field after each scenario indicated that many counselors tailored 
the session to the individual patient based on the personal and/or family history of 
cancer, rather than tailoring the session to the syndrome involved or the clinical 
actionability of the result. Genetic counselors are able to tailor recommendations by 
synthesizing information from test results, personal history, and family history, which 
allows them to provide patients a personalized risk assessment. When treatment and 
management options are discussed in the context of the individual, there is an increase 
in the quality of care. Other free responses focused on psychosocial support. This type 
of support is unique to genetic counselors in the context of genetic testing. The fact that 
respondents were able to tailor their session to the individual patient may be useful for 
informing counselors who are deciding how to approach a discrepancy and for informing 
future practice guidelines on variant discrepancies. Specifically that patient care requires 
individualization based on test results, personal history, family history, and psychosocial 
situation.  
 Laboratories and Other Resources 
        Most counselors (83%) indicated that their confidence in a classification depends 
on the laboratory providing it. Furthermore, additional support from the laboratories was 
the most commonly selected resource that would help with addressing a variant 
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discrepancy. These results indicated that interaction with the laboratory and which 
specific laboratory is involved were important factors when dealing with variant 
discrepancies. It also demonstrates the need for laboratories to provide support and 
resources to providers regarding hereditary cancer testing as well as the responsibilities 
laboratories have for communicating effectively with providers.  
        Following additional support from the laboratories involved, practice guidelines from 
a major society/organization and continuing education opportunities were the second 
and third most commonly selected resources, respectively. Currently, no guidelines 
address discrepancies in variant classification, including those from the National 
Comprehensive Cancer Network, American Society of Clinical Oncology, National 
Society of Genetic Counselors, or the guidelines on interpretation of sequence variants 
from the American College of Medical Genetics. 
        Furthermore, more than half (58%) of counselors chose functional studies as a 
resource that could help with addressing a variant discrepancy. Functional studies allow 
creation of the gene product from the DNA sequence. By creating the product from the 
sequence with the variant, researchers can ascertain if the DNA change maintains 
functionality of the gene. Functional studies were not widely utilized as a line of evidence 
for researching variants, which could be because this type of data was not available for 
many variants. This lack of availability could be due to the fact that they require a high 
monetary and temporal investment (Simpson et al., 2017). Despite these challenges, 
functional studies are known to be valuable for interpretation of variants, and performing 
these studies is of importance to advance knowledge of hereditary cancer (Amendola et 
al., 2015, Imyanitov et al., 2004, Richards et al., 2015). Fortunately, some genetic testing 
laboratories have started performing functional studies ("Myriad myChoiceTM HRD 
Technical Specifications."). 
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Limitations 
        The respondents to this survey may represent a skewed sample due to selection 
bias. Genetic counselors who have seen a variant discrepancy in practice or who 
conduct their own research on variants may have been more likely to take the survey.  
        The survey itself was created by the investigators and was not validated. 
Additionally, some responses had a small sample size, which limited the ability for 
statistical comparisons between groups. For example, there were a small number of 
respondents that order syndrome-specific testing most often (n=4, 2%). This made 
comparisons between that group and the group that ordered panel testing most often 
(n=186, 87%) less robust.  
Future Directions 
       These results call for additional resources to aid counselors in addressing variant 
discrepancies, including creation of a centralized database, additional support from 
laboratories, practice guidelines from a professional organization, continuing education 
on discrepancies, and functional studies. While respondents noted that having a central 
database owned by a non-profit with variant information from testing laboratories was 
desirable, additional research could help further define the ideal disease database and 
inform the creation of such a resource. A similar study could be conducted in the future 
to learn if counselors indeed see an increase in the number of variant discrepancies in 
practice over time.  
Conclusions 
         This investigation was unique because it was the first to address variant 
discrepancies from a clinical point of view. Cancer genetic counselors discovered 
fewer variant discrepancies in practice than suggested in previous literature, but 
addressing this issue is a concern for the genetic counseling profession since the vast 
majority of counselors have seen discrepancies in practice. Genetic counselors desire 
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further resources to aid in addressing variant discrepancies, including a centralized 
database, support from the genetic testing laboratories, practice guidelines from a major 
organization, continuing education opportunities, and functional studies. 
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